Actively Recruiting

Age: 18Years - 99Years
All Genders
ID05039216

Biobank for Inflammatory Chronic Diseases and Osteoporosis of Toulouse University Hospital

Led by University Hospital, Toulouse · Updated on 2026-03-19

2000

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to create a biobank for patients with chronic inflammatory rheumatism, including rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA), as well as those with osteoporosis. The goal is to identify biomarkers linked to how well patients respond to treatments, helping doctors make better treatment choices. The study is observational and sponsored by the University Hospital of Toulouse. Participants include patients beginning new biologic or targeted synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) for their conditions, as well as those with osteoporosis starting anti-osteoporotic treatments. Blood samples will be collected to study potential biomarkers. This biobank will support research on treatment response and disease severity. Participants will provide blood samples during the study. Researchers will measure treatment response using the European League Against Rheumatism (EULAR) response criteria after three months. The study involves follow-up to track biomarkers and treatment outcomes. The total participation period and specific visit schedules vary according to patient treatment and condition.

CONDITIONS

Brief Title

Biobank for Inflammatory Chronic Diseases and Osteoporosis

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 99 years
  • Diagnosed with chronic inflammatory rheumatism including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis, or with primary or secondary osteoporosis
  • Covered by National Health Assurance
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding
  • Unable to provide informed consent
  • Severe anemia with hemoglobin less than 10 g/L

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Sample Collection

Duration - Ongoing during the study period

Participants provide blood samples for the biobank to study biomarkers associated with chronic inflammatory diseases and osteoporosis.

1 baseline visit and 1 follow-up visit at 3 months

Long-term Monitoring

Duration - Up to 5 years

Participants are observed to assess clinical outcomes and biomarker associations related to disease severity and treatment response.

Periodic visits depending on clinical follow-up

Trial Site Locations

Total: 1 location

1

Purpan University Hospital

Toulouse, France, 31059

Actively Recruiting

Loading map...

Research Team

A

Adeline RUYSSEN-WITRAND, MD

D

Delphine THUILLEZ

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Evaluation of the Effect of Vitamin E (alpha-tocopherol) Sup...

Rheumatoid Arthritis

Actively Recruiting

2 locations

Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Deciphe...

Rheumatoid Arthritis

Actively Recruiting

1 location

A Dose Escalation Clinical Study to Evaluate the Safety, Tol...

Systemic Lupus Erythematosus

Actively Recruiting

12 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here